Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus NORGESTIMATE ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus NORGESTIMATE ETHINYL ESTRADIOL.
HYDROXYPROGESTERONE CAPROATE vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyprogesterone caproate is a synthetic progestin that acts as an agonist of the progesterone receptor. Its mechanism in preventing preterm birth is not fully understood but may involve suppression of uterine contractility, maintenance of cervical integrity, and modulation of the inflammatory response.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
250-500 mg intramuscularly once weekly. For recurrent preterm birth prevention: 250 mg intramuscularly weekly starting at 16-20 weeks gestation until 36 weeks.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Deslanoside
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyprogesterone caproate + Acetyldigitoxin
Terminal elimination half-life is approximately 7-8 days (range 5-14 days) due to slow release from the intramuscular depot, supporting weekly or biweekly dosing.
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Primarily renal as metabolites; approximately 50-60% of a dose is excreted in urine within 96 hours, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for approximately 30-40%.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category D/X
Category D/X
Progestin
Progestin + Estrogen
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Acetyldigitoxin."